Key Points
- CEO Kevin McNamara sold 2,000 shares on Nov. 24 at an average price of $437.55 for $875,100, reducing his stake by 2.08% to 94,197 shares valued at about $41.2 million.
- Chemed missed quarterly EPS estimates ($5.27 vs. $5.39) while revenue rose 3.1% year-over-year, and the company set FY2025 guidance at $22.00–$22.30 EPS versus analysts' consensus of $21.43.
- The stock trades with a market cap of ~$6.24 billion and a P/E of 23.31; the company recently declared a quarterly dividend of $0.60 (0.5% yield) and carries an average analyst target price of $574.25 ("Moderate Buy").
Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the company's stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $437.55, for a total transaction of $875,100.00. Following the sale, the chief executive officer directly owned 94,197 shares of the company's stock, valued at $41,215,897.35. This represents a 2.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Chemed Stock Up 1.0%
CHE stock opened at $440.86 on Wednesday. The company's 50-day moving average price is $441.47 and its two-hundred day moving average price is $475.99. The firm has a market cap of $6.24 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.69 and a beta of 0.43. Chemed Corporation has a 12 month low of $408.42 and a 12 month high of $623.60.
Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. During the same quarter in the prior year, the business posted $5.64 EPS. The business's revenue was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Equities analysts predict that Chemed Corporation will post 21.43 EPS for the current year.
Chemed Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Monday, November 17th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, November 17th. Chemed's payout ratio is currently 12.69%.
Institutional Investors Weigh In On Chemed
Several institutional investors and hedge funds have recently modified their holdings of CHE. SVB Wealth LLC purchased a new stake in Chemed during the first quarter worth about $30,000. WPG Advisers LLC purchased a new stake in shares of Chemed during the first quarter worth $32,000. Creekmur Asset Management LLC acquired a new stake in shares of Chemed in the second quarter valued at $28,000. Smartleaf Asset Management LLC raised its stake in shares of Chemed by 71.4% in the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company's stock valued at $27,000 after acquiring an additional 25 shares in the last quarter. Finally, First Horizon Corp purchased a new position in Chemed in the third quarter valued at $31,000. Hedge funds and other institutional investors own 95.85% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. Weiss Ratings reissued a "hold (c-)" rating on shares of Chemed in a research note on Wednesday, October 8th. Jefferies Financial Group raised Chemed from a "hold" rating to a "buy" rating and upped their target price for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Oppenheimer cut their price target on Chemed from $650.00 to $580.00 and set an "outperform" rating on the stock in a research note on Thursday, July 31st. Bank of America dropped their price target on shares of Chemed from $610.00 to $595.00 and set a "buy" rating for the company in a research note on Wednesday, September 10th. Finally, Royal Bank Of Canada cut their price target on shares of Chemed from $589.00 to $572.00 and set an "outperform" rating on the stock in a report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $574.25.
Read Our Latest Report on Chemed
Chemed Company Profile
(
Get Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
